Cell & Gene Analytics
Genome editing using designer nucleases such as CRISPR/Cas9, ZFNs, and TALENs allow the targeted introduction of genetic material into a specific locus of the mammalian genome. However, undesired on- and off-target genome modifications may arise, which could cause genomic instability and disrupt the functionality of otherwise normal genes, potentially causing safety concerns in pre-clinical and clinical studies. Additionally, immune responses generated by gene therapy must be well understood.
On- and Off-Target Analysis
ProtaGene offers comprehensive PCR and NGS-based assays for gene editing safety assessment. Our versatile and cost-effective assays interrogate both on- and off-target genomic alterations. In combination with robust in-house bioinformatics pipelines, our state-of-the-art assays reliably quantify the ratios between the desired targeted integration and non-desired outcomes such as translocations and indels.
We adapted the Shearing Extension Primer Tag Selection Ligation-Mediated PCR (S-EPTS/LM PCR) method to analyze on-target and off-target integrations arising from genome editing and use target enrichment sequencing (TES) for genome-wide detection and quantification of on- and off-target alterations.
Immune Repertoire Analysis
Adaptive immune response generates T cell and B cell receptors (TCRs and BCRs) that comprise an organism’s immune repertoire. Immune repertoire analysis has many applications, including cancer diagnosis and treatment, gene therapy development, and infectious diseases.
Several high-throughput technologies have emerged which allow comprehensive monitoring of the immune repertoire over time.
Although we have progressed from low-throughput to high-throughput analysis techniques, several challenges remain. Streamlined experimental pipelines for unique applications and customized bioinformatics tools for data analysis remain underdeveloped.
ProtaGene offers PCR- and target enrichment sequencing-based approaches for customized, high-throughput, and simultaneous analysis of T cell and B cell receptors from a wide range of sample input material.
Analytical Solutions from Research to Market
Gene & Cell Therapeutic Platform Expertise
Our deep experience assembling a broad range of gene and cell therapy platforms from research through commercialization helps the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key gene and cell therapy platform development areas include:
- AAVs (Multiple Serotypes and Engineered Vectors)
- Novel Systems
Complex, Envelope Vectors
- Novel Viruses
- Polynucleotide (RNA/DNA) Formulations
- Lipid Nanoparticles
- Zinc-finger Nucleases
Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.
Subscribe to Our Email List
Talk to Our Experts
Discover how ProtaGene can support your development programsContact Us